Exclusive Commercial Use of cDNA-uPA Transgenic Mouse Intellectual Property
First written in FY2016. 3 of 5 entries say "Restated". Latest entry: FY2020.
No other company in this theme has enough history to compare yet.
- FY2020RestatedAnnual report
「Compensation for non-use arising from the Company's exclusive commercial use of the intellectual property relating to the invention jointly filed by the Company, the Tokyo Metropolitan Institute of Medical Science and CHUGAI PHARMACEUTICAL CO.,LTD.」
The Company continues to disclose the agreement for the exclusive commercial use of intellectual property relating to cDNA-uPA transgenic mice. The contract runs through 27 April 2032. - FY2019Contract term disclosed through 2032Annual report
「Compensation for non-use arising from the Company's exclusive commercial use of the intellectual property relating to the invention jointly filed by the Company, the Tokyo Metropolitan Institute of Medical Science and CHUGAI PHARMACEUTICAL CO.,LTD.」
The disclosure states that the agreement for the exclusive commercial use of intellectual property relating to cDNA-uPA transgenic mice runs from 1 April 2016 to 27 April 2032. - FY2018RestatedAnnual report
「Compensation for non-use arising from the Company's exclusive commercial use of the intellectual property relating to the invention jointly filed by the Company, the Tokyo Metropolitan Institute of Medical Science and CHUGAI PHARMACEUTICAL CO.,LTD.」
The Company continues to disclose the agreement for the exclusive commercial use of intellectual property relating to cDNA-uPA transgenic mice. - FY2017RestatedAnnual report
「Compensation for non-use arising from the Company's exclusive commercial use of the intellectual property relating to the invention jointly filed by the Company, the Tokyo Metropolitan Institute of Medical Science and CHUGAI PHARMACEUTICAL CO.,LTD.」
The Company discloses an agreement for the exclusive commercial use of intellectual property relating to cDNA-uPA transgenic mice, with a contract term from April 2016 to March 2019. - FY2016First statedAnnual report
「Compensation for non-use arising from the Company's exclusive commercial use of the intellectual property relating to the invention jointly filed by the Company, the Tokyo Metropolitan Institute of Medical Science and CHUGAI PHARMACEUTICAL CO.,LTD.」
The Company has entered into an exclusive commercial use agreement for the jointly filed intellectual property relating to the cDNA-uPA host animals used to produce PXB mice.